Drug Target Review – Issue #4 2017
Posted: 5 December 2017 | Drug Target Review | No comments yet
Issue 4 of Drug Target Review looks at artificial intelligence in drug discovery and features In-Depth Focuses on Screening, Hit to Lead and Informatics.
- FOREWORD: Artificial intelligence in drug discover: how long before we see the real impact?
Richard Goodwin, Principal Scientist, AstraZeneca - APPLICATION NOTE: Performing NanoBRET with the Varioskan LUX multimode reader
Thermo Fisher Scientific - IN-DEPTH FOCUS: Screening
- APPLICATION NOTE: Screening for inhibitors of PD-1 and PD-L1 binding with AlphaLISA technology
PerkinElmer - APPLICATION NOTE: Next-generation sequencing sample preparation on the Thermo Scientific KingFisher platform
Thermo Fisher Scientific - PROTEOMICS: Proteogenomics research – on the frontier of precision medicine
Alicia Landeira, Rodrigo Garcia-Valiente, Maria Gonzalez-Gonzalez, Javier Carabias, Jonatan García, Rafael Góngora, Paula Diez and Manuel Fuentes, University of Salamanca - IN-DEPTH FOCUS: Hit to lead
- METABOLIC DISEASE: Patient-derived neural progenitor cells as a drug discovery model for mitochondrial diseases
Carmen Lorenz, Max Delbrück Center for Molecular Medicine (MDC) and Berlin Institute of Health (BIH); Gizem Inak and Alessandro Prigione, Max Delbrück Center for Molecular Medicine (MDC) - IN-DEPTH FOCUS: Informatics
The digital version of issue #4 2017 is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Drug Discovery, Drug Targets, Hit-to-Lead, Proteogenomics, Proteomics, Screening